Pfenex is a development and licensing biotechnology company focused on utilizing its proprietary protein production platform, Pfenex Expression Technology®, to develop protein therapeutics to improve existing therapies and create therapies for diseases still waiting to be addressed. The U.S. Food and Drug Administration-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. Co.'s other product includes PF743 (JZP-458), which it is developing in collaboration with Jazz Pharmaceuticals Ireland Limited for the treatment of acute lymphoblastic leukemia. Co. has added PF810, a peptide based therapeutic, to its wholly owned pipeline.
|
Free PFNX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.40 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: PFNX Stock Forecast Based on Zacks ABR data; powered by Xignite |